With growing numbers of hepatitis B virus (HBV)/ HIVcoinfected patients and the complexity of treating both diseases together, new treatment options and guidelines are available. This article reviews treatment and management options for HBV/HIV-coinfected patients.
Soriano V, Massimo P, Maurizio B, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005;19:221-240.
2.
Nunez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis.2005;5:374-382.
3.
Konopnicki D, Mocroft A, deWit S, et al; Euro SIDAGroup. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the Euro SIDA cohort. AIDS. 2005;19:593-601.
4.
New drug: Baraclude (entecavir). Pharmacist's Letter/ Prescriber's Letter. 2005;21:210-210
5.
Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology. 2004;39:857-861.
6.
Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. 2004;18:2039-2045.
7.
Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. April 07, 2005. Available at: http://aidsinfo.nih.gov/guidelines/adult/archive/AA_040705.pdf.
8.
US Food and Drug Administration. Pegasys [prescribing information. Available at: http://www.fda.gov/cder/foi/label/2005/103964s5037lbl.pdf. Accessed July 5, 2005.
9.
Hayden FG. Antiviral agents (nontretroviral). In: Hardman JG, Limbird LE, Goodman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed.New York, NY: McGraw-Hill; 2001:1332-1336.
10.
Thio CL. Management of chronic hepatitis B in the HIV-infected patient. AIDS Read. 2004;14:122-129, 133-133, 136-137.
11.
Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med.1997;336:347-356.
12.
Wong DK, Cheung AM, O'Rourke K, Naylor D, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patientswith hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med.1993;119:312-323.
13.
Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. NEngl JMed.1990;323:295-301.
14.
Di Martino V, Thevenot T, Colin J, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology. 2002;123:1812-1822.
15.
Lau GK, Luo KX, Marcellin P, et al. Peginterferon alfa-2a, lamivudine, and thhepatitis B. N Engl J Med.2005;352:2682-2695.
16.
Marcellin P, Lau GK, Bonino F, et al.Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBe Ag-negative chronic hepatitis B. N Engl J Med.2004;351:1206-1217.
17.
Cooksley WG. Peginterferon-alpha(2a) for the treatment of hepatitis Binfection. Expert Opin Pharmacother. 2005;6:1373-1380.
18.
AIDSinfo. Available at: www.aidsinfo.nih.gov. Accessed July 6, 2005.
19.
Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis.1999;180:607-613.
20.
Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis.2001;32:963-969.
21.
Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302-1306.
22.
Frampton JE, Perry CM. Emtricitabine: a review of its use in the management of HIV infection. Drugs. 2005;65:1427-1448.
23.
Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. Hepatology. 2005;43:60-66.
Alberti A, Clumeck N, Collins S, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis Band hepatitis Cin HIV co-infected patients. JHepatol. 2005;42:615-624.
26.
Gelinck LB, Claas EC, Kroon FP. The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients. J Hepatol. 2005;43:360-361.
27.
Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med.2003;348:808-816.
28.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med.2003;348:800-807.
29.
Benhamou Y, Thiabault V, Vig P. Long-term with adefovir dipivoxil 10 mg in patients with lamivudine-resistant HBV and HIV co-infection results in significant and sustained clinical improvement. Abstract presented at: 15th International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WeOrA1329.
30.
Dore G, Cooper D, Pozniak A, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis.2004;189:1185-1192.
31.
Van Bommel F, Wunscher T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology. 2002;36:507-508.
